Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 2
Submit an article Journal homepage
1,069
Views
22
CrossRef citations to date
0
Altmetric
Reviews

Novel sodium channel antagonists in the treatment of neuropathic pain

Mirko RivaraDipartimento di Farmacia, Università degli Studi di Parma, Via Area delle Scienze 27/A, I-43124Parma, ItalyCorrespondence[email protected]
&
Valentina ZulianiDipartimento di Farmacia, Università degli Studi di Parma, Via Area delle Scienze 27/A, I-43124Parma, Italy
Pages 215-226 | Received 14 Sep 2015, Accepted 16 Nov 2015, Published online: 14 Dec 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152:2204–2205.
  • Bogduk N, Merskey H. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle (WA): IASP Press; 1994.
  • Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin. Proc. 2015;90:532–545.
  • Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr. Pain Headache Rep. 2012;16:191–198.
  • Gaskin DJ, Richard P. The economic costs of pain in the United States. J. Pain. 2012;13:715–724.
  • Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ. 2014;348:f7656.
  • Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251.
  • Amir R, Argoff CE, Bennett GJ, et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J. Pain. 2006;7:S1–29.
  • England S. Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin. Investig. Drugs. 2008;17:1849–1864.
  • Dib-Hajj SD, Black JA, Waxman SG. Voltage-gated sodium channels: therapeutic targets for pain. Pain Med. 2009;10:1260–1269.
  • Bhattacharya A, Wickenden AD, Chaplan SR. Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics. 2009;6:663–678.
  • Dib-Hajj SD, Cummins TR, Black JA, et al. Sodium channels in normal and pathological pain. Annu. Rev. Neurosci. 2010;33:325–347.
  • Cohen CJ. Targeting voltage-gated sodium channels for treating neuropathic and inflammatory pain. Curr. Pharm. Biotechnol. 2011;12:1715–1719.
  • Eijkelkamp N, Linley JE, Baker MD, et al. Neurological perspectives on voltage-gated sodium channels. Brain. 2012;135:2585–2612.

• A complete review regarding sodium channels, sodium channel blockers and related diseases.

  • Habib AM, Wood JN, Cox JJ. Sodium channels and pain. Handb. Exp. Pharmacol. 2015;227:39–56.
  • Zuliani V, Patel MK, Fantini M, et al. Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential. Curr. Top. Med. Chem. 2009;9:396–415.
  • Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain. 2007;131:243–257.
  • Theile JW, Cummins TR. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front. Pharmacol. 2011;2:54.
  • Jukič M, Kikelj D, Anderluh M. Isoform selective voltage-gated sodium channel modulators and the therapy of pain. Curr. Med. Chem. 2014;21:164–186.

•• A comprehensive and very informative review about sodium channel selective targeting in pain.

  • Zuliani V, Rivara M, Fantini M, et al. Sodium channel blockers for neuropathic pain. Expert Opin. Ther. Pat. 2010;20:755–779.
  • Black JA, Cummins TR, Plumpton C, et al. Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. J Neurophysiol. 1999;82:2776–2785.
  • Kim CH, Oh Y, Chung JM, et al. Changes in three subtypes of tetrodotoxin sensitive sodium channel expression in the axotomized dorsal root ganglion in the rat. Neurosci Lett. 2002;323:125–128.
  • Lindia JA, Köhler MG, Martin WJ, et al. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain. 2005;117:145–153.
  • Nassar MA, Baker MD, Levato A, et al. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol. Pain. 2006;2:33.
  • Xie W, Strong JA, Ye L, et al. Knockdown of sodium channel NaV1.6 blocks mechanical pain and abnormal bursting activity of afferent neurons in inflamed sensory ganglia. Pain. 2013;154:1170–1180.
  • Xie W, Strong JA, Zhang J-M. Local knockdown of the NaV1.6 sodium channel reduces pain behaviors, sensory neuron excitability, and sympathetic sprouting in rat models of neuropathic pain. Neuroscience. 2015;291:317–330.
  • Deuis JR, Zimmermann K, Romanovsky AA, et al. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. Pain. 2013;154:1749–1757.
  • Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–898.
  • Dib-Hajj SD, Cummins TR, Black JA, et al. From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci. 2007;30:555–563.
  • Dib-Hajj SD, Yang Y, Black JA, et al. The Na(V)1.7 sodium channel: from molecule to man. Nat. Rev. Neurosci. 2013;14:49–62.
  • Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52:767–774.
  • Minett MS, Nassar MA, Clark AK, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat. Commun. 2012;3:791.
  • Lee J-H, Park C-K, Chen G, et al. A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. Cell. 2014;157:1393–1404.
  • Herzog RI, Cummins TR, Ghassemi F, et al. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J. Physiol. 2003;551:741–750.
  • Rush AM, Dib-Hajj SD, Liu S, et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. 2006;103:8245–8250.
  • Theile JW, Jarecki BW, Piekarz AD, et al. Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents. J. Physiol. 2011;589:597–608.
  • Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379:257–262.
  • Djouhri L, Fang X, Okuse K, et al. The TTX-resistant sodium channel Nav1.8 (SNS/PN3): expression and correlation with membrane properties in rat nociceptive primary afferent neurons. J. Physiol. 2003;550:739–752.
  • Ho C, O’Leary ME. Single-cell analysis of sodium channel expression in dorsal root ganglion neurons. Mol. Cell. Neurosci. 2011;46:159–166.
  • Chen X, Pang R-P, Shen K-F, et al. TNF-α enhances the currents of voltage gated sodium channels in uninjured dorsal root ganglion neurons following motor nerve injury. Exp. Neurol. 2011;227:279–286.
  • Gold MS, Weinreich D, Kim C-S, et al. Redistribution of Na(V)1.8 in uninjured axons enables neuropathic pain. J. Neurosci. 2003;23:158–166.
  • Novakovic SD, Tzoumaka E, McGivern JG, et al. Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J. Neurosci. 1998;18:2174–2187.
  • Joshi SK, Mikusa JP, Hernandez G, et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain. 2006;123:75–82.
  • Dong X-W, Goregoaker S, Engler H, et al. Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience. 2007;146:812–821.
  • Dib-Hajj SD, Black JA, Waxman SG. NaV1.9: a sodium channel linked to human pain. Nat. Rev. Neurosci. 2015;16:511–519.
  • Leipold E, Liebmann L, Korenke GC, et al. A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat. Genet. 2013;45:1399–1404.
  • Zhang XY, Wen J, Yang W, et al. Gain-of-function mutations in SCN11A cause familial episodic pain. Am. J. Hum. Genet. 2013;93:957–966.
  • Huang J, Han C, Estacion M, et al. Gain-of-function mutations in sodium channel NaV1.9 in painful neuropathy. Brain. 2014;137:1627–1642.
  • Han C, Yang Y, de Greef BTA, et al. The domain II S4-S5 linker in Nav1.9: A missense mutation enhances activation, impairs fast inactivation, and produces human painful neuropathy. NeuroMolecular Med. 2015;17:158–169.
  • Demant DT, Lund K, Finnerup NB, et al. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype. Pain. 2015. DOI:10.1097/j.pain.0000000000000266.
  • Hutson P, Backonja M, Knurr H. Intravenous lidocaine for neuropathic pain: a retrospective analysis of tolerability and efficacy. Pain Med. 2015;16:531–536.
  • Saeed T, Nasrullah M, Ghafoor A, et al. Efficacy and tolerability of carbamazepine for the treatment of painful diabetic neuropathy in adults: a 12-week, open-label, multicenter study. Int. J. Gen. Med. 2014;7:339–343.
  • Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev. 2014;4:CD005451.
  • Suter MR, Kirschmann G, Laedermann CJ, et al. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013;118:160–172.
  • Kharatmal SB, Singh JN, Sharma SS. Rufinamide improves functional and behavioral deficits via blockade of tetrodotoxin-resistant sodium channels in diabetic neuropathy. Curr. Neurovasc. Res. 2015;12:262–268.
  • Devor M. Sodium channels and mechanisms of neuropathic pain. J. Pain. 2006;7:S3–S12.
  • Kalia J, Milescu M, Salvatierra J, et al. From foe to friend: using animal toxins to investigate ion channel function. J. Mol. Biol. 2015;427:158–175.
  • Liu Y, Tang J, Zhang Y, et al. Synthesis and analgesic effects of μ-TRTX-Hhn1b on models of inflammatory and neuropathic pain. Toxins (Basel). 2014;6:2363–2378.
  • Green BR, Bulaj G, Norton RS. Structure and function of μ-conotoxins, peptide-based sodium channel blockers with analgesic activity. Future Med. Chem. 2014;6:1677–1698.
  • Layer RT, McIntosh JM. Conotoxins: therapeutic potential and application. Mar Drugs. 2006;4:119–142.
  • Twede VD, Miljanich G, Olivera BM, et al. Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads. Curr. Opin. Drug Discov. Devel. 2009;12:231–239.
  • Olivera BM. Conus peptides: biodiversity-based discovery and exogenomics. J. Biol. Chem. 2006;281:31173–31177.

•• A useful and instructive publication dealing with bioactive peptides.

  • Knapp O, McArthur JR, Adams DJ. Conotoxins targeting neuronal voltage-gated sodium channel subtypes: potential analgesics? Toxins (Basel). 2012;4:1236–1260.
  • Han T, Teichert R, Olivera B, et al. Conus venoms - A rich source of peptide-based therapeutics. Curr. Pharm. Des. 2008;14:2462–2479.
  • Klint JK, Smith JJ, Vetter I, et al. Seven novel modulators of the analgesic target NaV 1.7 uncovered using a high-throughput venom-based discovery approach. Br. J. Pharmacol. 2015;172:2445–2458.
  • Murray JK, Ligutti J, Liu D, et al. Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel. J. Med. Chem. 2015;58:2299–2314.
  • Hoyt SB, London C, Abbadie C, et al. A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain. Bioorg. Med. Chem. Lett. 2013;23:3640–3645.
  • Ho GD, Tulshian D, Bercovici A, et al. Discovery of pyrrolo-benzo-1,4-diazines as potent Nav1.7 sodium channel blockers. Bioorg. Med. Chem. Lett. 2014;24:4110–4113.
  • Yang S-W, Ho GD, Tulshian D, et al. Bioavailable pyrrolo-benzo-1,4-diazines as Na(v)1.7 sodium channel blockers for the treatment of pain. Bioorg. Med. Chem. Lett. 2014;24:4958–4962.
  • Sun S, Jia Q, Zenova AY, et al. The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7. Bioorg. Med. Chem. Lett. 2014;24:4397–4401.
  • McCormack K, Santos S, Chapman ML, et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. Proc. Natl. Acad. Sci. U. S. A. 2013;110:E2724–32.
  • Bagal SK, Bungay PJ, Denton SM, et al. Discovery and optimization of selective Nav1.8 modulator series that demonstrate efficacy in preclinical models of pain. ACS Med. Chem. Lett. 2015;6:650–654.
  • Freeman-Cook KD, Hoffman RL, Johnson TW. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry. Future Med. Chem. 2013;5:113–115.

• An enlightening paper about parameters for decision making in medicinal chemistry.

  • Lynch SM, Tafesse L, Carlin K, et al. Dibenzazepines and dibenzoxazepines as sodium channel blockers. Bioorg. Med. Chem. Lett. 2015;25:43–47.
  • Lynch SM, Tafesse L, Carlin K, et al. N-Aryl azacycles as novel sodium channel blockers. Bioorg. Med. Chem. Lett. 2015;25:48–52.
  • Yang J, Gharagozloo P, Yao J, et al. 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J. Med. Chem. 2004;47:1547–1552.
  • Shao D, Okuse K, Djamgoz MB. Protein-protein interactions involving voltage-gated sodium channels: post-translational regulation, intracellular trafficking and functional expression. Int. J. Biochem. Cell Biol. 2009;41:1471–1481.
  • Ilyin VI, Pomonis JD, Whiteside GT, et al. Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states. J. Pharmacol. Exp. Ther. 2006;318:1083–1093.
  • Whiteaker KL, Gopalakrishnan SM, Groebe D, et al. Validation of FLIPR membrane potential dye for high throughput screening of potassium channel modulators. J. Biomol. Screen. 2001;6:305–312.
  • Arkin MR, Connor PR, Emkey R, et al. FLIPRTM assays for GPCR and ion channel targets. Assay Guidance Manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2012.
  • Cole S, Bagal S, El-Kattan A, et al. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration. Xenobiotica. 2012;42:11–27.
  • Kikuchi R, De Morais SM, Kalvass JC. In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class. Drug Metab. Dispos. 2013;41:2012–2017.
  • Carbonara R, Carocci A, Roussel J, et al. Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres. Front. Pharmacol. 2015;6:155.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.